AstraZeneca PLC (LON:AZN - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the nine ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is GBX 7,935.67 ($98.56).
A number of analysts have weighed in on the company. Shore Capital restated a "buy" rating on shares of AstraZeneca in a report on Thursday, November 7th. JPMorgan Chase & Co. reiterated an "overweight" rating and issued a £140 ($173.87) target price on shares of AstraZeneca in a research note on Friday, November 22nd. Finally, Berenberg Bank reiterated a "buy" rating and issued a GBX 140 ($1.74) target price on shares of AstraZeneca in a report on Monday.
Read Our Latest Analysis on AstraZeneca
Insider Buying and Selling at AstraZeneca
In related news, insider Tony Mok acquired 1,500 shares of the stock in a transaction that occurred on Tuesday, November 19th. The stock was purchased at an average price of £126.80 ($157.48) per share, with a total value of £190,200 ($236,214.61). Also, insider Pascal Soriot purchased 20,000 shares of the firm's stock in a transaction on Thursday, November 14th. The shares were purchased at an average price of £102.03 ($126.71) per share, for a total transaction of £2,040,600 ($2,534,277.20). 0.04% of the stock is currently owned by company insiders.
AstraZeneca Trading Up 0.7 %
Shares of LON AZN traded up GBX 77.88 ($0.97) during trading hours on Thursday, hitting £113.10 ($140.46). 3,115,179 shares of the company traded hands, compared to its average volume of 42,219,648. The company's 50 day moving average price is £106.37 and its 200 day moving average price is £115.26. AstraZeneca has a 12 month low of GBX 9,461 ($117.50) and a 12 month high of £133.88 ($166.27). The stock has a market capitalization of £175.30 billion, a price-to-earnings ratio of 3,590.44, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 84.97.
AstraZeneca Company Profile
(
Get Free ReportAstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Read More
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
